Actively Recruiting

Early Phase 1
Age: 18Years - 90Years
All Genders
NCT04369560

Virtual Histology of the Bladder Wall for Bladder Cancer Staging

Led by Jodi Maranchie · Updated on 2025-12-17

42

Participants Needed

1

Research Sites

188 weeks

Total Duration

On this page

Sponsors

J

Jodi Maranchie

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a phase Ib study of the safety and performance of a novel intravesical contrast-enhanced Magnetic Resonance Imaging protocol for determination of bladder cancer stage prior to transurethral resection of bladder tumor (21 subjects) or prior to radical cystectomy for muscle invasive disease (21 subjects). Subjects will undergo a single MRI study: a pre-contrast, single breath hold image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and then a second, post-contrast image. Images will be reviewed by two dedicated abdominal radiologists, who are blinded to the pathologic staging, for determination of tumor presence and depth of bladder wall penetration.

CONDITIONS

Official Title

Virtual Histology of the Bladder Wall for Bladder Cancer Staging

Who Can Participate

Age: 18Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 90 years
  • Able to understand and willing to sign informed consent
  • Presence of papillary bladder tumor scheduled for transurethral resection or muscle invasive bladder cancer confirmed by biopsy and suitable for surgery
  • Performance status of ECOG 0 or 1
  • Normal kidney function defined as creatinine less than 1.5 times institutional upper limit or creatinine clearance ≥ 50 mL/min/1.73 m2
Not Eligible

You will not qualify if you...

  • Severe allergic reaction to gadobutrol or ferumoxytol
  • Severe claustrophobia preventing MRI completion
  • Presence of MRI-incompatible implanted devices or pacemakers
  • Known or suspected metastatic bladder cancer
  • Women who are pregnant, breastfeeding, or planning to become pregnant
  • Untreated urinary tract infection
  • Urethral stricture preventing catheter placement
  • Any other condition deemed high risk by the treating physician

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UPMC Hillman Cancer Center - Dept of Urology

Pittsburgh, Pennsylvania, United States, 15232

Actively Recruiting

Loading map...

Research Team

B

Brieanna Marino, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here